Business
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the closing of its previously announced initial public offering of an aggregate 3,000,000 Class A Ordinary Shares (“the Offering”) at a price of $4.00 per share (“th
About this update from Cuprina Holdings (cayman) Limited
[{"type":"image","alt":"Cuprina Holdings (Cayman) LTD","displaySize":"","headline":null,"caption":"Cuprina Holdings (Cayman) LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vs5DV_xDy69c4LSgVE319A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7","width":300,"height":73}},"lazy":false},{"type":"text","content":"SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the closing of its previously announced initial public offering of an aggregate 3,000,000 Class A Ordinary Shares (“the Offering”) at a price of $4.00 per share (“the Offering Price”) to the public, for a total of $12.0 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.","length":659,"tagName":"p"},{"type":"text","content":"The Company intends to use net proceeds from the Offering for expansion into new markets, R&D activities to expand its product portfolio, research and development activities, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.","length":300,"tagName":"p"},{"type":"text","content":"The shares began trading on the NASDAQ Stock Market LLC on April 10, 2025, under the symbol "CUPR".","length":109,"tagName":"p"},{"type":"text","content":"R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Winston & Strawn LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.","length":378,"tagName":"p"},{"type":"text","content":"“We are gratified to close this Offering,” said Cuprina chief executive David Quek. “Our chronic wound care products, we believe, are poised to gain esc...